Fiche centre
First Hospital of Shanxi Medical University
Taiyuan — China
Essais liés8clinical trials
VilleTaiyuanlocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07687186
Essais cliniques associés
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Maridebart cafraglutide | Insuffisance cardiaque | Phase 3 | NCT07037459 | MARITIME-HF — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | RECRUITING |
| Qishen Yiqi dripping pills 4 bags/time | Insuffisance cardiaque | Phase 2 | NCT04944706 | Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction | COMPLETED |
| Qishen Yiqi Dripping Pills 2 bags | Insuffisance cardiaque | Phase 3 | NCT07687186 | Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre | RECRUITING |
| Skeletal muscle biopsy (residual specimen) | Myopathies | À vérifier | NCT06101940 | Chinese Multicenter Clinical Outcome Cohort Study of Myotonic Dystrophy Type 1 (C-DMCOS-DM1) | ENROLLING_BY_INVITATION |
| Telitacicept | Myasthénie | Phase 3 | NCT06456580 | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | ACTIVE_NOT_RECRUITING |
| Efgartigimod IV | Myasthénie | Phase 3 | NCT06298552 | ADAPT SERON — A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| doublepres — The Diagnosis and Treatment of Resistant Hypertension, the Prevalence and the Prognosis | Hypertension | À vérifier | NCT01703780 | doublepres — The Diagnosis and Treatment of Resistant Hypertension, the Prevalence and the Prognosis | UNKNOWN |
| RC18 160mg | Myasthénie | Phase 2 | NCT04302103 | A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis | COMPLETED |